HYDERABAD: The US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotech’s Covid-19 vaccine, Covaxin, in the US.
This was announced by Ocugen, the Hyderabad-based vaccine maker’s partner for US, on Monday.